# Validation of CCR8 agonism as therapeutic strategy for treatment of (auto-)inflammation

A Data Management Plan created using DMPonline.be

Creators: n.n. n.n., n.n. n.n.

Affiliation: KU Leuven (KUL)

Template: KU Leuven BOF-IOF

Principal Investigator: n.n. n.n.

Project Administrator: n.n. n.n.

Grant number / URL: C3/23/073

**ID:** 207827

Start date: 01-01-2024

End date: 31-12-2025

### Project abstract:

CCR8 agonist compounds will be tested for potency in vitro in cell lines and for function on human T cells. Compounds with highest potency will be tested in a humanized in vivo model xenogeneic graft-vs-host disease for efficacy in expansion of regulatory T cells and disease amelioration.

Last modified: 31-05-2024

## Validation of CCR8 agonism as the rapeutic strategy for treatment of (auto-)inflammation

#### Research Data Summary

List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data.

Dataset name / ID	Description	New or reuse	Digital or Physical data	II loto Tama			Physical volume
		Indicate: N(ew data) or E(xisting data)	Indicate: <b>D</b> (igital) or <b>P</b> (hysical)	Indicate: Audiovisual Images Sound Numerical Textual Model SOftware Other (specify)		Indicate: <1GB <100GB <1TB <5TB >5TB NA	
compound collection	small molecule compound libraries agonistic or antagonistic to human CCR8	N	P	chemical		NA	
flow cytometric data		N	D	N	.fcs	<5TB	

If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type:

NA

Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.

- Yes, human subject data (Provide SMEC or EC approval number below)
- Yes, animal data (Provide ECD reference number below)

human peripheral blood cells from healthy donors will be purchased from BRC (rest material, s-number S65883 approved) humanized mice will be treated with compounds and human cells analysed ex vivo (ECD 135/2021, will be amended/renewed as required)

Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).

No

Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, ...)? If so, please comment per dataset or data type where appropriate.

• Yes
* compounds may be valorised upon functional validation
Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer agreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what restrictions are in place.
• No
Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted.
• No
All IP is currently with KU Leuven.
Documentation and Metadata
Clearly describe what approach will be followed to capture the accompanying information necessary to keep data understandable and usable, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded).
All data and accompanying information will be stored on KU Leuven L-drive.
Will a metadata standard be used to make it easier to find and reuse the data?
If so, please specify which metadata standard will be used.
If not, please specify which metadata will be created to make the data easier to find and reuse.
• No
NA
Data Storage & Back-up during the Research Project
Where will the data be stored?
Large Volume Storage
KU Leuven L-drive and archived in K-drive.
How will the data be backed up?
Standard back-up provided by KU Leuven ICTS for my storage solution

Is there currently sufficient storage & backup capacity during the project?

If no or insufficient storage or backup capacities are available, explain how this will be taken care of.

Yes

How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?

restricted KU leuven folder access.

What are the expected costs for data storage and backup during the research project? How will these costs be covered?

Cost are according to KU Leuven standard prices per TB.

Cost will be covered by C3/23/073 funding and other funding sources for storage times that exceed this funding.

Data Preservation after the end of the Research Project

Which data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of the project?

In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...).

• All data will be preserved for 10 years according to KU Leuven RDM policy

Where will these data be archived (stored and curated for the long-term)?

• Large Volume Storage (longterm for large volumes)

What are the expected costs for data preservation during the expected retention period? How will these costs be covered?

Cost are according to KU Leuven standard prices per TB.

Cost will be covered by C3/23/073 funding and other funding sources for storage times that exceed this funding.

**Data Sharing and Reuse** 

Will the data (or part of the data) be made available for reuse after/during the project? Please explain per dataset or data type which data will be made available.

• Yes, as open data

upon publication and in line with LRD advice on IP protection, licensing agreements and patenting goals.

If access is restricted, please specify who will be able to access the data and under what conditions.
NA
Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)?
Please explain per dataset or data type where appropriate.
• Yes, intellectual property rights
Where will the data be made available?
If already known, please provide a repository per dataset or data type.
• KU Leuven RDR (Research Data Repository)
W7
When will the data be made available?
Upon publication of research results
Which data usage licenses are you going to provide?
If none, please explain why.
to be defined.
Do you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please provide it here.
• Yes, a PID will be added upon deposit in a data repository
What are the expected costs for data sharing? How will these costs be covered?
publication costs. these depend on the journal and will be covered by C3/23/073 funding.
Responsibilities
Responsibilities  Who will manage data documentation and metadata during the research project?

## Who will manage data storage and backup during the research project?

Profs Susan Schlenner, Dominique Schols and Wim Dehaen Drs Steven De Jonghe and Tom Van Loy

## Who will manage data preservation and sharing?

Profs Susan Schlenner, Dominique Schols and Wim Dehaen Drs Steven De Jonghe and Tom Van Loy

# Who will update and implement this DMP?

Prof Susan Schlenner Dr Steven De Jonghe